Universal template approach to drug design: Polyamines as selective muscarinic receptor antagonists

Journal of Medicinal Chemistry

Volumn 41, Issue 21, 1998, Pages 4150-4160

  Bolognasi, Maria L ^a   Minarini, Anna ^a   Budriesi, Roberta ^a   Cacciaguerra, Silvia ^a   Chiarini, Alberto ^a   Spampinato, Santi ^a   Tumiatti, Vincenzo ^a   Melchiorre, Carlo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHOCTRAMINE; METHYLSCOPOLAMINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PIRENZEPINE; POLYAMINE; TRIPINAMIDE; TRIPITRAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN CORTEX; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FEMALE; GUINEA PIG; HEART; HEART LEFT ATRIUM; ILEUM; LIPOPHILICITY; MALE; NONHUMAN; RAT; SUBMANDIBULAR GLAND;

EID: 0032497593     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm981038d     Document Type: Article

References (38)

1. For a review, see: (a) Hulme, E. C.; Birdsall, N. J. M.; Buckley, N. J. Muscarinic Receptor Subtypes. Annu. Rev. Pharmacol. Toxicol. 1990, 30, 633-673.
2. (b) Caulfield, M. P. Muscarinic Receptors-Characterization, Coupling and Function. Pharmacol. Ther. 1993, 58, 319-379.
3. For a review, see: (a) Hulme, E. C.; Birdsall, N. J. M.; Buckley, N. J. Muscarinic Receptor Subtypes. Annu. Rev. Pharmacol. Toxicol. 1990, 30, 633-673. (b) Eglen, R. M.; Hegde, S. S.; Watson, N. Muscarinic Receptor Subtypes and Smooth Muscle Function. Pharmacol. Rev. 1996, 48, 531-565. (c) Eglen, R. M.; Hegde, S. S.; Watson, N. Muscarinic Receptor Subtypes and Smooth Muscle Function. Pharmacol. Rev. 1996, 48, 531-565.
4. 1 Antagonists: Drug Design and Discovery. Drug Discovery Today 1997, 2, 341-350.
5. McKinney, M.; Coyle, J. T. The Potential for Muscarinic Receptor Subtype-Specific Pharmacotherapy for Alzheimer's Disease. Mayo Clin. Proc. 1991, 66, 1225-1237.
6. Melchiorre, C.; Yong, M. S.; Benfey, B. G.; Belleau, B. Molecular Properties of the Adrenergic α Receptor. 2. Optimum Covalent Inhibition by Two Different Prototypes of Polyamine Disulfides. J. Med. Chem. 1978, 21, 1126-1132.
7. (a) Melchiorre, C. Polymethylene Tetraamines: a New Generation of Selective Muscarinic Antagonists. Trends Pharmacol. Sci. 1988, 9, 216-220.
8. (b) Melchiorre, C.; Minarini, A.; Angeli, P.; Giardinà, D.; Gulini, U.; Quaglia, W. Polymethylene Tetraamines as Muscarinic Receptor Probes. Trends Pharmacol. Sci. 1989, Suppl. IV, 55-59.
9. 2 Antagonists. Med. Res. Rev. 1990, 3, 327-349.
10. Melchiorre, C.; Cassinelli, A.; Quaglia, W. Differential Blockade of Muscarinic Receptor Subtypes by Polymethylene Tetraamines. Novel Class of Selective Antagonists of Cardiac M-2 Muscarinic Receptors. J. Med. Chem. 1987, 30, 201-204.
11. Melchiorre, C.; Angeli, P.; Brasili, L.; Giardinà, D.; Pigini, M.; Quaglia, W. Polyamines: A Possible "Passe-Partout" for Receptor Characterization. Actual. Chim. Thér. - 15e série 1988, 149-168.
12. 13C NMR Chemical Shift Assignments of Spermidine, Spermine, and Homologs. Biophys. Chem. 1983, 17, 67-74.
13. Melchiorre, C. Tetramine Disulfides: A New Tool in α-Adrenergic Pharmacology. Trends Pharmacol. Sci. 1981, 2, 209-211.
14. Melchiorre, C.; Recanatini, M.; Bolognesi, M. L.; Filippi, P.; Minarini, A. Polyamines: A Case of Multiple Yet Specific Receptor Recognition. Curr. Top. Med. Chem. 1993, 1, 43-65.
15. Doughty, M. B.; Chu, S. S.; Miller, D. W.; Li, K.; Tessel, R. E. Benextramine: A Long-Lasting Neuropeptide Y Receptor Antagonist. Eur. J. Pharmacol. 1990, 185, 113-114.
16. Bergeron, R. J.; Weimar, W. R.; Wu, Q.; Austin, J. K., Jr.; McManis, J. S. Impact of Polyamine Analogues on the NMDA Receptor. J. Med. Chem. 1995, 38, 425-428.
17. Bergeron, R. J.; McManis, J. S.; Liu, C. Z.; Feng, Y.; Weimar, W. R.; Luchetta, G. R.; Wu, Q.; Ortiz-Ocasio, J.; Vinson, J. R. T.; Kramer, D.; Porter, C. Antiproliferative Properties of Polyamines Analogues: A Structure-Study. J. Med. Chem. 1994, 37, 3464-3476.
18. Seiler, N.; Atanassov, C. L. The Natural Polyamines and the Immune System. In Progress in Drug Research; Jucker, E., Ed.; Birkhäuser Verlag: Basel, 1994; Vol. 43, pp 87-141.
19. Dorje, F.; Wess, J.; Lambrecht, G.; Tacke, R.; Mutschler, E.; Brann, M. R. Antagonist Binding Profiles of Five Cloned Human Muscarinic Receptor Subtypes. J. Pharmacol. Exp. Ther. 1991, 256, 727-733.
20. 2 Muscarinic Receptor Antagonists. J. Med. Chem. 1993, 36, 3734-3737.
21. Minarini, A.; Bolognesi, M. L.; Budriesi, R.; Canossa, M.; Chiarini, A.; Spampinato, S.; Melchiorre, C. Design, Synthesis, and Biological Activity of Methoctramine-Related Tetraamines Bearing an 11-Acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one Moiety: Structural Requirements for Optimum Occupancy of Muscarinic Receptor Subtypes As Revealed by Symmetrical and Unsymmetrical Polyamines. J. Med. Chem. 1994, 37, 3363-3372.
22. Melchiorre, C.; Minarini, A.; Spampinato, S.; Tumiatti, V. Design, Synthesis and Biological Activity of Some Tetraamines Related to Methoctramine and 4-DAMP. Bioorg. Med. Chem. Lett. 1995, 5, 785-790.
23. Eberlein, W. G.; Engel, W.; Hasselbach, K. M.; Mayer, N.; Mihm, G.; Rudolf, K.; Doods, H. Tricyclic Compounds as Selective Muscarinic Antagonists: Structure Activity Relationships and Therapeutic Implications. In Trends in Receptor Research; Angeli, P., Gulini, U., Quaglia, W., Eds.; Elsevier Science Publishers B.V.: Amsterdam, 1992; pp 231-249.
24. 2-Selective Antimuscarinics. J. Med. Chem. 1993, 36, 162-165.
25. Melchiorre, C.; Quaglia, W.; Picchio, M. T.; Giardinà, D.; Brasili, L.; Angeli, P. Structure-Activity Relationships among Methoctramine-Related Polymethylene Tetraamines. Chain-Length and Substitution Effects on M-2 Muscarinic Receptor Blocking Activity. J. Med. Chem. 1989, 32, 79-84.
26. 1-Selective Antimuscarinics Related to Pirenzepine. J. Med. Chem. 1988, 37, 1169-1174.
27. This compound was synthesized from N,N'-dimethyl-1,8-octanediamine following the procedure reported by Atwell, G. J.; Denny, W. A. Monoprotection of α,ω-Alkanediamines with the N-Benzyloxycarbonyl Group. Synthesis 1984, 27, 1032-1033.
28. Arunlakshana, D.; Schild, H. O. Some Quantitative Uses of Drug Antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
29. 2 and Receptor Differentiation: A Statistical Analysis of Competitive Antagonism. Life Sci. 1979, 25, 637-654.
30. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
31. 2 Muscarinic Blocking Activity as Revealed by Symmetrical and Unsymmetrical Polyamines. Farmaco 1991, 46, 417-434.
32. Partition coefficients (log P) of tetraamines as free bases were calculated with CLOGP Program implemented in the C-QSAR program version 1.87, BioByte, Claremont, CA, 1994.
33. Van Rossum, J. M. Cumulative Dose-Response Curves. II. Technique for the Making of Dose-Response Curves in Isolated Organs and the Evaluation of Drug Parameters. Arch. Int. Pharmacodyn, 1963, 143, 299-330.
34. 3H]-N-Methylscopolamine Binding to Muscarinic Receptors in the Rat Central Nervous System: Evidence for the Existence of Three Classes of Binding Sites. Mol. Pharmacol. 1986, 30, 305-314.
35. Michel, A. D.; Delmendo, R.; Stefanich, E.; Whiting, R. L. Binding Characteristics of the Muscarinic Receptor Subtype of the NG 108-15 Cell Line. Arch. Pharmacol. 1989, 340, 62-67.
36. 4 Binding Sites in Rabbit Lung, Chicken Heart, and NG 108-15 Cells. Mol. Pharmacol 1990, 38, 805-815.
37. Munson, P. J.; Rodbard, D. LIGAND: A Versatile Computerised Approach for the Characterization of Ligand Binding Systems. Anal. Biochem. 1980, 107, 220-239.
38. Tallarida, R. J.; Murray, R. B. Manual of Pharmacological Calculations with Computer Programs, Version 4.2; Springer-Verlag: New York, 1991.